Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US2016002339A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016002339-A1 |
| Application number | US-201514724058-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 28, 2015 |
| Priority date | May 4, 2010 |
| Publication date | Jan 7, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1 . A composition comprising isolated monoclonal anti-EGFR antibody vb, comprising heavy chain SEQ ID NO: 10 and light chain SEQ ID NO: 21, in a pharmaceutically acceptable carrier. 2 . A composition comprising isolated monoclonal anti-EGFR antibody vj, comprising heavy chain SEQ ID NO: 8 and light chain SEQ ID NO: 19, in a pharmaceutically acceptable carrier. 3 . A composition comprising isolated monoclonal anti-EGFR antibody vf, comprising heavy chain SEQ ID NO: 3 and light chain SEQ ID NO: 14, in a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
from primates, e.g. man · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016002339A1 cover?
- Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39558. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jan 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).